Search company, investor...

Micronics Microfluidics

Founded Year



Acquired | Acquired

Total Raised


About Micronics Microfluidics

Micronics is advancing a portfolio of point of care products for disease detection, diagnosis and treatment monitoring. The company employs an estate in microfluidics and related technologies that make it possible to process biological and environmental samples directly in disposable devices and to perform highly accurate and affordable tests in a fraction of the time required by most molecular diagnostic tests in use today. Micronics is involved in the research and development of near patient Point of Care devices for disease diagnosis, treatment monitoring and blood testing, and also provides product development for third-party clients. In September 2011, Micronics was acquired by Sony Corp's US subsidiary, Sony Corporation of America. Micronics' valuation was not disclosed nor were other terms of the transaction.

Headquarters Location

8463 154th Avenue NE Building G

Redmond, Washington, 98052,

United States


Missing: Micronics Microfluidics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Micronics Microfluidics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Micronics Microfluidics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Micronics Microfluidics is included in 2 Expert Collections, including Health Monitoring & Diagnostics.


Health Monitoring & Diagnostics

702 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting


Clinical Encounter Tech

625 items

Latest Micronics Microfluidics News

Sony Backing Organ-on-Chip Technology

Mar 19, 2013

Gavin Corley News , Rehab About 18 months ago we reported on Sony’s foray into the life-sciences space with the acquisitions of Micronics Inc. and three other companies working on micro-fluidic, lab-on-chip diagnostic technologies. This week, Sony Digital Audio Disc Corporation announced high profile collaboration with Harvard’s Wyss Institute for Biologically Inspired Engineering to advance their pioneering o rgan-on-chip  technologies. The organ-on-chip technologies in question have previously graced the pages of Medgadget  and refer to flexible polymer substrates, which contain hollow micro-fluidic channels lined by living human cells. These systems act as surrogate, lab-friendly organs which allow researchers to study the physiological and mechanical behavior of the cells in real-time. The hope is that these surrogate organs will allow for an accelerated and lower cost means of studying drug interactions in humans without the need for animal studies. According to the Wyss Institute press release there are now a number of these organ-on-chips devices in development with lung, heart, liver, kidney, bone marrow, and gut-on-a-chip systems already in the works. Clearly, Sony sees a role for their growing stable of microfluidics and manufacturing technologies in the evolution of these new-age organs. However, they are only the latest in a series of major backers for the project with the FDA, the NIH and DARPA already supporting the effort. We will be watching this very one closely. Gavin Corley Gavin holds a first-class Bachelor’s degree in Electronic Engineering degree from the University of Limerick and a Ph.D. in Biomedical Engineering from the National University of Ireland, Galway. He is currently a post-doctoral research and project leader at the NUI Galway where he has spent the last 2 years leading the product development and commercialization of two novel technologies for the management of varicose veins and chronic venous leg ulcers. He has published several research papers in the fields of anatomy, physiology and medical physics and is the lead author of one patent application to date.In his free time Gavin has been known to swim, cycle and hum a tune or two. Related Posts

Micronics Microfluidics Frequently Asked Questions (FAQ)

  • When was Micronics Microfluidics founded?

    Micronics Microfluidics was founded in 1996.

  • Where is Micronics Microfluidics's headquarters?

    Micronics Microfluidics's headquarters is located at 8463 154th Avenue NE, Redmond.

  • What is Micronics Microfluidics's latest funding round?

    Micronics Microfluidics's latest funding round is Acquired.

  • How much did Micronics Microfluidics raise?

    Micronics Microfluidics raised a total of $17.41M.

  • Who are the investors of Micronics Microfluidics?

    Investors of Micronics Microfluidics include Sony, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ardesta LLC, SWMF Life Science Fund and 5 more.

  • Who are Micronics Microfluidics's competitors?

    Competitors of Micronics Microfluidics include Natus Medical, Brain Tunnelgenix Technologies, Binx Health, MedShape, PulmonX, Amsino International, Autonomic Technologies, Neuro Kinetics, Prometheus Laboratories, Acelity and 54 more.

Compare Micronics Microfluidics to Competitors


Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

Atonomics Logo

Atonomics develops a point of care diagnostic device based on an electro-mechanical concept. This technology changes the way that DNA and antibodies are used in point of care diagnosis.

NDO Surgical

Medical devices for the treatment of severe gastrointestinal disorders

hanse chemie GmbH

Micronics, Inc. is a developer of near patient in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. The Company employs a core patent estate in microfluidics -- the ability to miniaturize complex tests onto credit card size disposable devices. Per the company, tests that today take hours to days in a central laboratory environment are processed on a Micronics disposable device in seconds to minutes.

Binx Health Logo
Binx Health

Binx Health is an in vitro diagnostics Point-of-Care (POC) company that provides at-home STI testing. The platform also includes evidence-based testing, counseling, treatment, and follow up in order to increase screening and reduce infections.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.